SOPHiA GENETICS™

SOPHiA DDM™ Multimodal Analytics Solutions

Unlocking predictive insights from Real-World Data for smarter clinical R&D

Discovering new and unmet needs, pinpointing super-responders, and streamlining clinical trial design with the support of AI-powered analytics and the global network of **SOPHiA DDM™.**

DATA SOURCES

Native Data

- From clinical research and routine analysis– today in Lung Cancer, tomorrow in Brain, Breast, Kidney, and others

New Data

- From new observational studies
- From new modalities or treatments arms added to ongoing studies
- From new partnerships with AMCs (e.g., MSKCC)

Your Data

- From your clinical studies



*Product in development - Technology and concepts in development. May not be available for sale.

DISCOVER THE FUTURE OF MULTIMODAL ANALYSIS

Uncover multimodal biomarker signatures

Draw insights from real-world data to understand treatment responses and population outcomes

Develop and train multimodal algorithms

Leverage multimodal signatures to guide the development and training of models and algorithms

Stratify patient populations

Harness multimodal algorithms to generate predictive insights, improving trial efficiency and go-to-market strategies

The information provided in this flyer are presenting products or concepts in development. They are not products available for sale and not intended foruse in diagnostic procedures or treatment decisions.

Going beyond Genomics in Lung Cancer



LUNG CANCER

Lung cancer is the leading cause of cancer death, accounting for **1/5** of all cancer deaths.[1] Patients are often diagnosed at **Stage IV** when the tumor has already spread beyond the lung.[2-4]

At SOPHiA GENETICS we partnered with AstraZeneca to gain novel insights into the **uncharted journey of lung cancer patients**. Combining radiomics, digital pathology, genomics, and clinical and biological data, we aim to **go beyond single biomarkers** to provide a multimodal perspective and support clinical researchers in identifying signatures to understand relapse and treatment responses.[5]

> *"By harnessing the power of advanced AI and machine learning models, we can integrate multiple forms of data to generate critical insights that can inform prognosis and response to therapy at the individual patient level. This approach aligns with our focus on developing personalized cancer treatments, which is currently driven by genomic-based biomarkers, and has the potential to elevate precision oncology into a truly multimodal, interconnected health ecosystem.*

Greg Rossi, PhD
Senior Vice President
Oncology Europe & Canada
AstraZeneca

[1]. WHO. Lung Fact Sheet. Available at: http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. [2]. Abernethy A.P., et al. 2017. PLoS ONE. 12(6):e0178420. doi: 10.1371/journal.pone.0178420.[3]. Cheema P.K. et al. 2019. Curr Oncol. 26(1):37-42. doi: 10.3747/co.25.4096. [4]. Cancer.net. Available at: https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/introduction [5]. Peters S. et al. 2022. J Thorac Oncol. 17(9):S39-S41. doi: 10.1016/j.jtho.2022.07.073

Other indications of interest

- BRAIN CANCER
- BREAST CANCER
- KIDNEY CANCER
- HEAD & NECK CANCER
- NEURO-ENDOTHELIAL CANCER
- ADRENAL CANCER

About SOPHiA GENETICS

SOPHiA GENETICS is a health tech company democratizing Data-Driven Medicine (DDM) to improve health outcomes and economics worldwide. By unlocking the power of new-generation health data for cancer and rare disease management, the SOPHiA DDM™ platform allows clinical researchers to act with precision and confidence. The company's innovative approach and patented machine learning-based algorithms enable a community of more than 750 institutions to share knowledge. Together, SOPHiA GENETICS and its users are fostering a new era in healthcare.

Ready to Expand your Clinical R&D Programs?

Learn how we can work together to generate more insights from multimodal data.

Get in touch >